| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ProGRP |
| Uniprot No | P07492 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 54-121aa |
| 氨基酸序列 | STGESSSVSERGSLKQQLREYIRWEEAARNLLGLIEAKENRNHQPPQPKALGNQQPSWDSEDSSNFKD |
| 预测分子量 | 35.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ProGRP重组蛋白的3篇示例参考文献，内容基于常见研究方向模拟整理：
---
1. **文献名称**：Expression and Purification of Recombinant ProGRP in Escherichia coli for Immunoassay Development
**作者**：Chen H, Li X, et al.
**摘要**：本研究构建了ProGRP基因的重组质粒，利用大肠杆菌表达系统实现高效表达，并通过镍柱亲和层析和离子交换层析纯化获得高纯度蛋白。纯化后的ProGRP重组蛋白成功应用于ELISA试剂盒开发，验证了其免疫反应活性。
2. **文献名称**：Clinical Utility of Recombinant ProGRP as a Biomarker in Small Cell Lung Cancer Monitoring
**作者**：Wang J, Liu R, et al.
**摘要**：通过分析150例小细胞肺癌患者血清样本，发现重组ProGRP蛋白检测的灵敏度和特异性分别达到92%和88%，显著优于传统标志物。研究证实其在疾病复发监测和疗效评估中的临床应用潜力。
3. **文献名称**：Structural Insights into Recombinant ProGRP by Circular Dichroism and Molecular Dynamics Simulations
**作者**：Kim S, Tanaka M, et al.
**摘要**：采用圆二色谱和分子动力学模拟解析重组ProGRP的二级结构特征，发现其N端结构域具有高度柔性，可能与受体结合功能相关。结果为靶向ProGRP的药物设计提供了分子基础。
---
**说明**：以上文献为模拟示例，涵盖ProGRP重组蛋白的制备、临床验证及结构研究。实际应用中建议通过PubMed或Web of Science检索真实文献。
ProGRP (Pro-Gastrin-Releasing Peptide) is a precursor protein of gastrin-releasing peptide (GRP), a neuropeptide involved in neurotransmission, cell proliferation, and hormone regulation. GRP binds to the bombesin receptor subtype 2 (BB2), activating pathways that influence processes like tumor growth and inflammation. ProGRP is enzymatically cleaved to release the bioactive GRP, but its full-length form has gained clinical significance as a biomarker, particularly in small cell lung cancer (SCLC).
Recombinant ProGRP is engineered using genetic cloning techniques, where the PROGRP gene is inserted into expression systems (e.g., bacterial, mammalian, or insect cells) to produce purified proteins for research and diagnostics. Unlike GRP, which degrades rapidly, ProGRP exhibits greater stability in circulation, making it more reliable for clinical assays. Elevated serum ProGRP levels are strongly associated with SCLC, where it outperforms other markers like neuron-specific enolase (NSE) in specificity and sensitivity. It aids in diagnosis, treatment monitoring, and detecting recurrence.
Structurally, recombinant ProGRP retains critical domains, including the signal peptide, pro-region, and mature GRP sequence, ensuring antigenicity for antibody-based tests. Its production enables standardization of immunoassays, improving consistency across diagnostic kits. Beyond oncology, ProGRP studies explore its role in neuroendocrine disorders and inflammatory conditions.
Research on recombinant ProGRP also supports therapeutic development, such as antibody-drug conjugates targeting GRP-receptor-positive cancers. However, challenges remain in optimizing expression yields and minimizing cross-reactivity in assays. Ongoing efforts focus on refining its clinical utility and exploring novel applications in personalized medicine. Overall, ProGRP recombinant protein serves as a vital tool bridging basic research and translational oncology.
×
